Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Related Articles by Review for PubMed (Select 22130117)

1.

Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.

Bryce A, Ryan CJ.

Clin Pharmacol Ther. 2012 Jan;91(1):101-8. doi: 10.1038/clpt.2011.275. Epub 2011 Nov 30. Review.

PMID:
22130117
2.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
3.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

4.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
5.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

PMID:
19558559
6.

Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.

Sharifi N.

Anticancer Agents Med Chem. 2009 Dec;9(10):1046-51. Review.

PMID:
19719456
7.

Agents that target androgen synthesis in castration-resistant prostate cancer.

Ferraldeschi R, de Bono J.

Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f. Review.

PMID:
23337755
8.

Novel agents for the management of castration-resistant prostate cancer.

Haddad H, Garcia JA.

Curr Opin Urol. 2012 May;22(3):175-82. doi: 10.1097/MOU.0b013e3283523ba0. Review.

PMID:
22472509
9.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
10.

Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.

Pezaro CJ, Mukherji D, De Bono JS.

Drug Discov Today. 2012 Mar;17(5-6):221-6. doi: 10.1016/j.drudis.2011.12.012. Epub 2011 Dec 19. Review.

PMID:
22198164
11.

[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].

Boissier E, Loriot Y, Vignot S, Massard C.

Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French.

PMID:
24793632
12.

Overcoming castration resistance in prostate cancer.

Tsao CK, Small AC, Galsky MD, Oh WK.

Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b. Review.

PMID:
22472508
13.

Abiraterone acetate in castration-resistant prostate cancer.

Iacovelli R, Palazzo A, Procopio G, Gazzaniga P, Cortesi E.

Anticancer Drugs. 2012 Mar;23(3):247-54. doi: 10.1097/CAD.0b013e32834e696c. Review.

PMID:
22123334
14.

Androgen receptor antagonists in castration-resistant prostate cancer.

Rathkopf D, Scher HI.

Cancer J. 2013 Jan-Feb;19(1):43-9. doi: 10.1097/PPO.0b013e318282635a. Review.

15.

Novel strategies in the treatment of castration-resistant prostate cancer (Review).

Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F.

Int J Oncol. 2012 May;40(5):1313-20. doi: 10.3892/ijo.2012.1364. Epub 2012 Feb 9. Review.

PMID:
22322981
16.

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.

MacVicar GR, Hussain MH.

Curr Opin Oncol. 2013 May;25(3):252-60. doi: 10.1097/CCO.0b013e32835ff161. Review.

PMID:
23511665
17.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

18.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
19.

Novel hormonal approaches in prostate cancer.

Friedlander TW, Ryan CJ.

Curr Oncol Rep. 2009 May;11(3):227-34. Review.

PMID:
19336015
20.

Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.

Nguyen MM, Wang Z.

Minerva Urol Nefrol. 2008 Mar;60(1):15-29. Review.

PMID:
18427432
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk